Search Results

There are 1734 results for: content related to: Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

  1. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Article first published online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  2. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Article first published online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  3. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Article first published online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  4. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 162–175, Dr Yaowei Zhu, Dr Chuanpu Hu, Dr Ming Lu, Dr Sam Liao, Dr Joseph C. Marini, Dr Jennifer Yohrling, Dr Newman Yeilding, Dr Hugh M. Davis and Dr Honghui Zhou

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008329556

  5. Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 257–267, Dr Honghui Zhou, Dr Chuanpu Hu, Dr Yaowei Zhu, Dr Ming Lu, Dr Sam Liao, Dr Newman Yeilding and Dr Hugh M. Davis

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009343695

  6. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

    British Journal of Dermatology

    Volume 170, Issue 2, February 2014, Pages: 398–407, P. Rich, M. Bourcier, H. Sofen, S. Fakharzadeh, Y. Wasfi, Y. Wang, U. Kerkmann, P.-D. Ghislain, Y. Poulin and on behalf of the PHOENIX 1 investigators

    Article first published online : 18 FEB 2014, DOI: 10.1111/bjd.12632

  7. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 89, Issue 5, October 2010, Pages: 351–363, Pauline L. Martin, Clifford Sachs, Noritaka Imai, Hideshi Tsusaki, Satoru Oneda, Qun Jiao and George Treacy

    Article first published online : 10 JUN 2010, DOI: 10.1002/bdrb.20250

  8. You have free access to this content
    Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

    British Journal of Pharmacology

    Volume 160, Issue 4, June 2010, Pages: 810–820, Wolfgang Weger

    Article first published online : 1 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00702.x

  9. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Article first published online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  10. You have free access to this content
    The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 1145–1152, T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi, on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups

    Article first published online : 29 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11142.x

  11. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

    The Journal of Dermatology

    Volume 39, Issue 9, September 2012, Pages: 761–769, Hidemi NAKAGAWA, Brad SCHENKEL, Mai KATO, Takeshi KATO, Atsuyuki IGARASHI and The Japanese Ustekinumab Study Group

    Article first published online : 12 MAR 2012, DOI: 10.1111/j.1346-8138.2012.01521.x

  12. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives

    Annals of the New York Academy of Sciences

    Volume 1222, Issue 1, March 2011, Pages: 30–39, Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick, Honghui Zhou, Kavitha Goyal, Brad Schenkel, Jill Giles-Komar, Mary Ann Mascelli and Cynthia Guzzo

    Article first published online : 22 MAR 2011, DOI: 10.1111/j.1749-6632.2011.05963.x

  13. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 7, July 2011, Pages: 851–857, L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne and H.L. Sofen

    Article first published online : 27 APR 2011, DOI: 10.1111/j.1468-3083.2011.04082.x

  14. Ustekinumab in clinical practice: response depends on dose and previous treatment

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 4, April 2012, Pages: 508–513, V. Ruiz Salas, L. Puig and A. Alomar

    Article first published online : 12 NOV 2011, DOI: 10.1111/j.1468-3083.2011.04325.x

  15. Novel biologic therapies in development targeting IL-12/IL-23

    Journal of the European Academy of Dermatology and Venereology

    Volume 24, Issue s6, October 2010, Pages: 5–9, PCM Van De Kerkhof

    Article first published online : 9 SEP 2010, DOI: 10.1111/j.1468-3083.2010.03830.x

  16. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    L. Puig, A. López, E. Vilarrasa and I. García

    Article first published online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  17. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland

    British Journal of Dermatology

    Volume 166, Issue 1, January 2012, Pages: 189–195, P.M. Laws, A.M. Downs, R. Parslew, B. Dever, C.H. Smith, J.N. Barker, B. Moriarty, R. Murphy, B. Kirby, A.D. Burden, S. McBride, A.V. Anstey, S. O’Shea, N. Ralph, C. Buckley, C.E.M. Griffiths and R.B. Warren

    Article first published online : 27 DEC 2011, DOI: 10.1111/j.1365-2133.2011.10638.x

  18. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

    British Journal of Dermatology

    Volume 168, Issue 5, May 2013, Pages: 990–998, E.M. Baerveldt, A.J. Onderdijk, D. Kurek, M. Kant, E.F. Florencia, A.S. Ijpma, P.J. van der Spek, J. Bastiaans, P.A. Jansen, J.W.J. van Kilsdonk, J.D. Laman and E.P. Prens

    Article first published online : 25 APR 2013, DOI: 10.1111/bjd.12175

  19. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

    British Journal of Dermatology

    Volume 168, Issue 4, April 2013, Pages: 844–854, K.A. Papp, C.E.M. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, Y. Wasfi, D. Chan, M.-C. Hsu, V. Ho, P.D. Ghislain, B. Strober, K. Reich and on behalf of the PHOENIX 1, PHOENIX 2 and ACCEPT Investigators

    Article first published online : 25 MAR 2013, DOI: 10.1111/bjd.12214

  20. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

    British Journal of Dermatology

    Volume 164, Issue 4, April 2011, Pages: 862–872, K. Reich, R.G. Langley, M. Lebwohl, P. Szapary, C. Guzzo, N. Yeilding, S. Li, M-C. Hsu and C.E.M. Griffiths

    Article first published online : 4 APR 2011, DOI: 10.1111/j.1365-2133.2011.10257.x